Humacyte (HUMA) KOL event summary

Introduction and agenda

• The webinar focused on unmet needs in dialysis access for kidney failure patients, highlighting phase III trials of an acellular tissue engineered vessel (ATEV) versus traditional fistula access.

• Presentations included KOLs discussing clinical challenges, trial results, and future directions, followed by a Q&A session.

KOL background and credentials

• Dr. Prabir Roy-Chaudhury is co-director of the UNC Kidney Center, past President of the American Society of Nephrology, and has 25 years of nephrology experience.

• Dr. Mohamad A. Hussain is a vascular and endovascular surgeon at Brigham and Women's Hospital, involved in multiple ATEV clinical trials.

Market insights and analysis

• Over 550,000 patients in the U.S. require hemodialysis, with vascular access being a major challenge.

• 80% of new hemodialysis patients start with a catheter, leading to high infection rates, costs, and poor quality of life, especially for women.

• Women have higher rates of catheter dependence due to anatomical factors, resulting in worse outcomes and higher mortality.